Mobble
Health · Drug development · published 2026-08-14 · via Endpoints News

Biogen's felzartamab gains first regulatory nod in China for multiple myeloma

Biogen's monoclonal antibody felzartamab has been approved in China for the treatment of multiple myeloma. The drug is authorized for second-line patients in combination with lenalidomide and dexamethasone. This marks the first global approval for felzartamab.

Read the full article at Endpoints News →
Related stories
Bristol's new myeloma drug wins FDA approval, opening a new treatment category · Cancer research
J&J's Imaavy becomes first approved therapy for rare anemia · Drug development
FDA grants accelerated approval to Bristol Myers Squibb's iberdomide for relapsed multiple myeloma · Cancer research
Ultragenyx wins first FDA nod for gene therapy targeting rare metabolic disease · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “Biogen's monoclonal antibody felzartamab wins first global approval in China.” Browse more stories.